Identification of <i>HEPACAM2</i> as a novel and specific marker of small cell carcinoma
With its remarkable specificity, high expression, presence in early disease, and extracellular secretion, HEPACAM2 could be a potential diagnostic cell surface biomarker for early SCLC detection. These findings warrant further investigation into its role in the pathobiology of SCLC.
Authors
- Masaru Miyagi (ORCID: https://orcid.org/0000-0003-4325-1216)
- Giulia Romano (ORCID: https://orcid.org/0000-0001-5847-4266)
- Michela Saviana (ORCID: https://orcid.org/0000-0003-2915-8752)
- Abhishek Ajay (ORCID: https://orcid.org/0009-0001-8258-8447)
- Afshin Dowlati (ORCID: https://orcid.org/0000-0003-4535-6839)
- Minh Quang Lam (ORCID: https://orcid.org/0000-0003-1373-4241)
- Shelby Rose Kopp
- Craig D. Peacock (ORCID: https://orcid.org/0000-0001-8139-8628)
- Suzy Yoon (ORCID: https://orcid.org/0000-0001-6177-5668)
- Gary Wildey (ORCID: https://orcid.org/0000-0001-7105-1313)
- Hung‐Ying Kao (ORCID: https://orcid.org/0000-0003-4535-0314)
- Karen McColl (ORCID: https://orcid.org/0000-0003-0133-5198)
- Peronne Joseph
- Wadad Mneimneh (ORCID: https://orcid.org/0000-0001-5555-1991)
- Patrick Nana‐Sinkam
- Han Wang (ORCID: https://orcid.org/0000-0002-8557-7292)
- Brandon Grubb
- Zixi Yun
Institutions
- Virginia Commonwealth University (US)
- Cleveland Clinic Lerner College of Medicine (US)
- University Hospitals Seidman Cancer Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Cancer
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1002/cncr.35557
- Citations
- 3
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- U.S. Department of Defense
- National Cancer Institute